What the laboratory can and cannot say

The routine evidence in this case supports preeclampsia through new hypertension and proteinuria. It does not show a laboratory severe feature or hemolysis pattern at the draw. That distinction is important because neither a mildly low platelet count nor a small AST elevation alone should be inflated into a severe-feature conclusion.

The Elecsys ratio adds a method-bound risk statement. A ratio at or below 38 supported a one-week rule-out outcome in the PROGNOSIS study population, but a ratio above 38 had limited positive predictive value and does not diagnose preeclampsia. The cleared device is used with clinical assessment and other laboratory findings, not instead of them.

The only definitive treatment is delivery of the placenta, while laboratory evidence supports monitoring and timing decisions. Before each release, check local validation, current instructions for use, local critical values, escalation procedure, and whether the patient matches the intended use. When evidence is discordant, release what the method measured, state the validated boundary, and escalate the unresolved question through the local clinical pathway.